Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

PrECOG: Added everolimus extends PFS for HR positive, HER2 negative breast cancer

SABCS 2016

6 - 10 Dec 2016

Published: 7 Dec 2016

Views: 2270

Rating:

Save

Dr Noah Kornblum - Montefiore Medical Center, New York, USA

Dr Kornblum presents results at the San Antonio Breast Cancer Symposium 2016 from a randomised, double-blind phase II trial of everolimus vs placebo in combination with fulvestrant from HR /HER- metastatic breast cancer for patients resistant of aromatase inhibitor therapy.

The addition of everolimus doubled median PFS to 10.4 months, with adverse events at a higher, but manageable, severity, consistent with previous assessment of everolimus in the BOLERO-2 trial.

Related Videos

Advancements in paediatric Acute lymphoblastic leukemia management

Dr Ruchi Aujla - Balco Medical Center, Raipur, India

Advancements in paediatric Acute lymphoblastic leukemia management ( Dr Ruchi Aujla - Balco Medical Center, Raipur, India )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Breast Cancer

Dr Nita Nair - Apollo Cancer Centres, Mumbai

Breast Cancer ( Dr Nita Nair - Apollo Cancer Centres, Mumbai )

The Southeast Asian Breast Cancer Symposium; background, aims and successes

Carolyn Taylor - Executive Director, Global Focus on Cancer

The Southeast Asian Breast Cancer Symposium; background, aims and successes ( Carolyn Taylor - Executive Director, Global Focus on Cancer )

Low-cost detection and treatment strategies for breast cancer patients in LMICs

Dr Anupama Mane - Ruby Hall Clinic, Pune, India

Low-cost detection and treatment strategies for breast cancer patients in LMICs ( Dr Anupama Mane - Ruby Hall Clinic, Pune, India )

Choosing wisely in breast cancer

Dr Anupama Mane - Ruby Hall Clinic, Pune, India

Choosing wisely in breast cancer ( Dr Anupama Mane - Ruby Hall Clinic, Pune, India )

The current status of multiple myeloma diagnosis and treatment

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

The current status of multiple myeloma diagnosis and treatment ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

Overview of the management of HER2-low breast cancer patients

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Overview of the management of HER2-low breast cancer patients ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

More from ecancer